Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Curative Radiotherapy Clear all
Recruiting Phase 2 Interventional

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

NCT05491226
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Pembrolizumab, Radiation Therapy, Axatilimab
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

NCT04988074
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
Cemiplimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting No phase listed Observational

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

NCT06410300
View directory record Official record
Conditions
Lung Cancer
Interventions
Curative Radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
Bo Lu
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Columbia, Missouri • New Brunswick, New Jersey • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Results available

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View directory record Official record
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

NCT00833248
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Goserelin, Bicalutamide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00003139
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications
Interventions
pilocarpine hydrochloride, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

NCT01345539
View directory record Official record
Conditions
Oligometastatic Disease
Interventions
Stereotactic Radiosurgery (SRS), Chemotherapy
Radiation · Drug
Lead sponsor
Steven Burton
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity

NCT06860425
View directory record Official record
Conditions
Mobile Applications, Cancer Patients
Interventions
RestoreMe
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

NCT03697304
View directory record Official record
Conditions
Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
Interventions
Ezabenlimab, BI 754111, BI 836880
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Results available

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

NCT00140556
View directory record Official record
Conditions
Head and Neck Cancer, Pharynx Cancer
Interventions
Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib
Radiation · Drug
Lead sponsor
David M. Brizel, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
Interventions
GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

NCT02114229
View directory record Official record
Conditions
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions
alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
9
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

NCT04220775
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Interventions
Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Suspended Phase 3 Interventional

Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet

NCT05351294
View directory record Official record
Conditions
Radiation Therapy, Metastatic Cancer
Interventions
Questionnaires, Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Other · Combination Product
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Jersey City, New Jersey • New Brunswick, New Jersey • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Surgery and Radiotherapy in People With Breast Cancer

NCT07053085
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions
Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
Procedure · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional

Preservation of Ovarian Tissue and Chemo-Radiotherapy

NCT02429349
View directory record Official record
Conditions
Endocrine Disorders of Female Reproductive System, Secondary Infertility, Infertility Involuntary
Interventions
surgery
Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
8 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Germantown, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting No phase listed Observational

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

NCT04305613
View directory record Official record
Conditions
Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions
Chemoradiation
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Esthetics of Dental Composite and Adhesive System

NCT03716349
View directory record Official record
Conditions
Cavities of Teeth
Interventions
Pulp vitality testing, Photos, local and/or topical anesthetic, rubber dam, tooth surface cleaned, enamel margins, Adhesive Systems, cavity preparation, Shade selection using Easy Shade 5, Light Curing, Contoured and polished, Consent, Health Questionnaire, xray, Release of medical information signed, Oral Exam, Teeth Assessment, Clinical Assessment, Tokuyama Universal Bond, ScotchBond
Diagnostic Test · Other · Drug + 3 more
Lead sponsor
Erica Teixeira
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Virtual Personalized Exercise Program for Lung Cancer Patients

NCT06540495
View directory record Official record
Conditions
Lung Cancer
Interventions
Salaso Virtual Exercise Program
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

NCT04916002
View directory record Official record
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
Interventions
vidutolimod, cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1Phase 2 Interventional

Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00086931
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional

Neurotropic Melanoma of the Head and Neck

NCT00975520
View directory record Official record
Conditions
Melanoma
Interventions
Observation, Radiation Therapy
Other · Radiation
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 25, 2026, 10:15 AM EDT